CEL-SCI Corp. | Cash Flow

Fiscal year is October-September. All values USD Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
9,170.90
27,366.30
34,692.20
11,512.50
14,363.30
Depreciation, Depletion & Amortization
364.10
231.80
720.50
664.00
632.90
Other Funds
7,473.10
4,638.70
6,425.00
10,759.10
6,812.40
Funds from Operations
16,279.90
22,495.80
27,546.70
21,607.60
20,542.80
Changes in Working Capital
2,731.30
432.20
3,713.30
1,474.90
6,750.90
Net Operating Cash Flow
13,548.60
22,928.00
23,833.30
23,082.50
13,791.90
Capital Expenditures
132.80
138.90
93.50
34.20
17.00
Net Investing Cash Flow
132.80
138.90
93.50
34.20
17.00
Issuance/Reduction of Debt, Net
6.90
8.10
8.50
1,112.30
2,741.00
Net Financing Cash Flow
9,781.90
31,538.90
21,139.90
20,308.00
13,260.30
Net Change in Cash
3,899.40
8,472.00
2,786.90
2,808.70
548.60
Free Cash Flow
13,650.60
23,032.00
23,906.70
23,113.90
13,802.40
Change in Capital Stock
9,788.80
31,547.00
21,148.40
21,420.30
10,519.30

About CEL-SCI

View Profile
Address
8229 Boone Boulevard
Vienna Virginia 22182
United States
Employees -
Website http://www.cel-sci.com
Updated 07/08/2019
CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus or human papillomavirus co-infected patients.